RU2017138187A - A method of reducing the hypertensive effect of cobalt chloride calcitonin - Google Patents
A method of reducing the hypertensive effect of cobalt chloride calcitonin Download PDFInfo
- Publication number
- RU2017138187A RU2017138187A RU2017138187A RU2017138187A RU2017138187A RU 2017138187 A RU2017138187 A RU 2017138187A RU 2017138187 A RU2017138187 A RU 2017138187A RU 2017138187 A RU2017138187 A RU 2017138187A RU 2017138187 A RU2017138187 A RU 2017138187A
- Authority
- RU
- Russia
- Prior art keywords
- cobalt chloride
- calcitonin
- reducing
- hypertensive effect
- administered
- Prior art date
Links
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 title claims 4
- 102000055006 Calcitonin Human genes 0.000 title claims 3
- 108060001064 Calcitonin Proteins 0.000 title claims 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title claims 3
- 229960004015 calcitonin Drugs 0.000 title claims 3
- 230000001631 hypertensive effect Effects 0.000 title claims 2
- 238000000034 method Methods 0.000 title claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 238000010171 animal model Methods 0.000 claims 2
- 241000972773 Aulopiformes Species 0.000 claims 1
- 235000019515 salmon Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2017138187A RU2699800C2 (en) | 2017-11-01 | 2017-11-01 | Method for reducing hypertensive effect of cobalt chloride with calcitonin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2017138187A RU2699800C2 (en) | 2017-11-01 | 2017-11-01 | Method for reducing hypertensive effect of cobalt chloride with calcitonin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017138187A3 RU2017138187A3 (en) | 2019-05-06 |
| RU2017138187A true RU2017138187A (en) | 2019-05-06 |
| RU2699800C2 RU2699800C2 (en) | 2019-09-11 |
Family
ID=66430090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017138187A RU2699800C2 (en) | 2017-11-01 | 2017-11-01 | Method for reducing hypertensive effect of cobalt chloride with calcitonin |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2699800C2 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2359338C1 (en) * | 2008-02-20 | 2009-06-20 | Федеральное государственное образовательное учреждение высшего профессионального образования "Чувашский государственный университет им. И.Н. Ульянова" | Arterial hypertension simulation method |
| US20110152183A1 (en) * | 2008-06-25 | 2011-06-23 | Novo Nordisk A/S | Derivatised hybrid peptides of amylin and salmon calcitonin |
| CA2755068C (en) * | 2009-03-12 | 2018-11-06 | Nordic Bioscience A/S | Treatment of diabetes and metabolic syndrome |
| RU2455982C1 (en) * | 2010-11-09 | 2012-07-20 | Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "УрНИИДВиИ" Минздравсоцразвития России) | Method of treating patients with mycosis fungoides |
-
2017
- 2017-11-01 RU RU2017138187A patent/RU2699800C2/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017138187A3 (en) | 2019-05-06 |
| RU2699800C2 (en) | 2019-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123460T1 (en) | COMPOUNDS AND METHODS FOR TREATING AN EPILEPSY DISORDER | |
| EA201790568A1 (en) | APPLICATION OF DOUBLE AGONIST OF GLP-1 / GLYCAGON RECEPTORS FOR PROLONGED ACTION FOR THE TREATMENT OF NON-ALCOHOLIC LIVER DISEASE | |
| EA201792592A1 (en) | PHARMACEUTICAL PREPARATIONS CONTAINING TENOFOVIR AND EMTRICITABIN | |
| EA201792591A1 (en) | PHARMACEUTICAL PREPARATIONS | |
| EA201492010A1 (en) | APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| EA202091112A1 (en) | SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION | |
| FI3383385T4 (en) | Melflufen dosage regimens for cancer | |
| ZA201904591B (en) | Dexmedetomidine or medetomidine for use in treating separation anxiety in dogs | |
| EA202190429A1 (en) | Bioavailable oral dosage forms | |
| RU2014148977A (en) | PROCESSING FISH POPULATION WITH LUFENURON | |
| RU2020120876A (en) | A PHARMACEUTICAL COMPOSITION CONTAINING ANTAGONIST OF MINERALOCORTICOID RECEPTORS AND ITS APPLICATION | |
| RU2017138187A (en) | A method of reducing the hypertensive effect of cobalt chloride calcitonin | |
| RU2015134356A (en) | PEPTIDE | |
| EA202191063A1 (en) | NEW DOSE FORM | |
| WO2016130518A3 (en) | Methods and compositions for treating muscle disease and disorders | |
| AR101227A1 (en) | COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN | |
| RU2013130302A (en) | APPLICATION OF THE ADSORPED HOMOGENATE OF A NUTRITION AND VITAMIN D3 OR VITAMINS OF GROUP D, AND / OR THEIR ACTIVE METABOLITES FOR PREVENTION AND TREATMENT OF VIRAL DISEASES | |
| EA201791038A1 (en) | TREATMENT OF INPUTABILITY OF ENTERAL FOOD | |
| RU2014145029A (en) | A method for the prevention of cancer of the liver and esophagus in laboratory animals | |
| RU2016143153A (en) | COMBINATIONS OF ANTI-CANCER MEDICINES | |
| EA202090416A1 (en) | METHODS FOR TREATING GASTROPARESIS SYMPTOMS USING A VELUSETRAGA | |
| MX2013008996A (en) | Novel pharmaceutical system of biphasic delivery for treating pain and inflammation. | |
| RU2016139885A (en) | A method for the treatment of hepatosis in cattle | |
| RU2014107146A (en) | METHOD FOR PREVENTING A CARCINOGENIC EFFECT OF DIETHYLNITROSAMINE IN EXPERIMENTAL ANIMALS | |
| RU2011111891A (en) | METHOD FOR PREVENTION OF SYSTEMIC AMYLOIDOSIS AND ITS NEPHROPATHIC FORM IN EXPERIMENTAL ANIMALS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20191102 |